Market Cap | 19.24M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -13.77M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 22.00% |
Sales | 122.11k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 16.00% |
Dividend | N/A | Price/Book | 0.59 | EPS next 5Y | - | 52W High Chg | -95.00% |
Recommedations | - | Quick Ratio | 1.41 | Shares Outstanding | 6.14M | 52W Low Chg | 73.00% |
Insider Own | 54.71% | ROA | -23.42% | Shares Float | 2.56M | Beta | 1.47 |
Inst Own | 0.32% | ROE | -46.62% | Shares Shorted/Prior | 72.71K/91.11K | Price | 0.96 |
Gross Margin | -207.79% | Profit Margin | - | Avg. Volume | 248,108 | Target Price | - |
Oper. Margin | -27,202.19% | Earnings Date | May 10 | Volume | 19,763 | Change | -1.35% |
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
LIN LAWRENCE K | Other Other | Dec 27 | Option | 0.25 | 413,368 | 103,342 | 413,368 | 12/28/21 |